RxDoctor Payments Data

Anthony Cifelli, MD

Internal Medicine · Morris Plains, NJNPI 1245228451

Payments from drug & device makers

$3,074in general payments, 2019–2025

Across 98 payments — averaging $31.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$807
  • AbbVie$727
  • Novo Nordisk$567
  • Biohaven Pharmaceuticals, Inc.$216
  • Amarin Pharma, Inc.$153
  • Idorsia Pharmaceuticals US Inc$120
  • plus $483 from 15 others

What the payments were for

  • Food & beverage$3,05499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,074 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$156,869
Medicare patients
623
Services billed
3,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$148,874
JardianceEmpagliflozin54$66,070
MounjaroTirzepatide48$59,188
FarxigaDapagliflozin Propanediol46$44,981
RybelsusSemaglutide15$36,456
JanuviaSitagliptin Phosphate19$30,976
EliquisApixaban20$25,193
XareltoRivaroxaban12$16,206
Glipizide-MetforminGlipizide/Metformin Hcl67$5,444
CreonLipase/Protease/Amylase13$5,256
Metoprolol Succinate326$4,534
SynthroidLevothyroxine Sodium56$4,460
Semglee (Yfgn) PenInsulin Glargine-Yfgn11$4,292
Metoprolol-HydrochlorothiazideMetoprolol/Hydrochlorothiazide45$4,207
Levothyroxine Sodium376$3,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$567$185,330160 claims
AstraZenecaFarxiga$807$44,98146 claims
PfizerEliquis$32$25,19320 claims
Johnson & JohnsonXarelto$39$16,20612 claims
AbbVieCreon, Synthroid$727$9,71669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Morris Plains

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →